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Abstracts / Biol Blood Marrow Transplant 20 (2014) S128eS150S142number of PIRCHES for potential donors prior to HSCT may
allow reducing complications after HLA-mismatched HSCT
by avoiding donors that can recognize higher numbers of
PIRCHE. The present observations indicate that selection of
HLA-mismatched donors with low numbers of PIRCHES may
lead to 5-year survival probabilities similar to 10/10 matched
unrelated donors. These observations require, however,
conﬁrmation in other cohorts. Moreover, the PIRCHES
concept may also be valuable in other HSCT settings, such as
CB transplantation and HSCTwith a 10/10matched unrelated
donor that is mismatched for HLA-DPB1.Figure 1. Kaplan Meier Curves for DFS and OS196
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Background: Umbilical cord blood (UCB) is increasingly used
as a source of unrelated donor hematopoietic cells. Advan-
tages of UCB include immediate graft availability, higher
likelihood of acceptable match, and reduced likelihood and
severity of graft vs. host disease (GVHD). Incorporation of
Busulfan (Bu) with Fludarabine (Flu) in a reduced intensity
conditioning (RIC) regimen has the potential advantages of
improved disease control and acceptable toxicity.
Patients: Eighteen patients (pts), median age 57 years (yrs)
(range 27-70), median weight 83 kg (range 54-127), Karnof-
sky performance status 80-100%, underwent double unit UCB
transplantation for hematologic malignancies (AML 44%; ALL
22%) between January 2012 and February 2013. Early disease
was seen in 44%, intermediate 12%, and advanced 44%.
Adverse cytogeneticswere present in 39%. CMVseropositivity
was seen in 16/18 (89%) pts. Hematopoietic cell trans-
plantation comorbidity index (HCT-CI) scores were HCT-CI
score 0, 44%; score 1-2, 44%; and score > 3, 12%.
Methods: UCB units were 4-6/6 HLA-A, -B antigen, and DRB1
allele matched to the pt, with median 4.36 x 107 total
nucleated cells(TNC)/kg (range 2.86e6.93) per transplant.
RIC regimen included Bu 0.8 mg/kg IV q6h x 8 doses, Flu 35
mg/m2 IV/day x 5, TBI 300-450cGy total, and ATG 1.5 mg/kg/
day x 3. Cyclosporine and mycophenolate mofetil were given
for GVHD prophylaxis.
Results: Median follow up of surviving pts was 12 months.
Day 180 overall survival (OS) was 72%. One yr OS and non-
relapse mortality (NRM) were 45% and 49%, respectively.
Relapse occurred in 1 pt. Cumulative incidence of myeloid
and platelet engraftment was 83% and 72%,median 20 and 47
days (d), respectively. First chimerism evaluation occurred at
median 21 d, all evaluable patients had 95% donor chime-
rism. At day 100, 79% of evaluable pts had single UCB unit
dominance. Acute GVHD grades II-IV occurred in 39% and
grades III-IV in 6% of patients. Chronic GVHD occurred in 17%
during the follow up period. CMV reactivation occurred in 9/
15 at risk pts, median 41 d post-transplant (range 18-54). A
median of 3 CMV reactivations per pt was observed. Two
died with CMV disease during ﬁrst reactivation, while 2others developed ganciclovir resistance. EBV reactivation
occurred in 5/17 pts, 1 pt developed Post Transplant Lym-
phoproliferative Disorder (PTLD) unresponsive to therapy.
One death was due to disseminated mucor.
Discussion: Flu/Bu based RIC regimen for double unit UCB
transplantation is associated with rapid donor chimerism
and possibly reduced disease relapse. Acute GVHD incidence
was low. Failure to achieve neutrophil and platelet engraft-
ment and high incidence of viral reactivation led to signiﬁ-
cant morbidity and high 1 yr NRM. Deﬁnitive conclusions
based on the data are limited by small patient numbers and
short follow up. Further strategies are needed to improve
immune function after RIC double unit UCB transplant.197
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